Moms in the Make America Healthy Again (MAHA) movement gathered outside the U.S. Supreme Court on Monday, chanting “People vs. Poison” to denounce the Trump administration’s handling of glyphosate, the active ingredient in Roundup. The rally coincided with oral arguments in a high‑profile product‑liability case, drawing media attention to the growing grassroots backlash.

Justices are hearing claims that Bayer’s flagship weedkiller caused cancer in tens of thousands of users, a dispute that could reshape liability exposure for agro‑chemical giants. The agency’s refusal to ban glyphosate despite mounting scientific controversy fuels litigation risk, while the administration’s defensive stance has sparked political friction with MAHA activists.

Investors watch the case closely; a sizable judgment could force Bayer to allocate billions for settlements, pressuring its balance sheet and prompting a reassessment of pesticide portfolios across the sector. Meanwhile, consumer‑focused retailers may accelerate product‑line reviews to avoid exposure. The protest underscores how regulatory uncertainty translates directly into market volatility.

Congressional committees have already slated hearings on glyphosate safety, reflecting bipartisan concern amplified by the MAHA demonstrations. Lawmakers may push for stricter labeling or renewed EPA review, steps that could tighten compliance costs for growers and reshape demand for alternative herbicides.